Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities.  Peloton Therapeutics’ lead program, PT2385, is a first-in-class small molecule targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of renal and other cancers.


Click above image for video discussing Peloton’s HIF-2a inhibitor.

Peloton Therapeutics, Inc. Presents Clinical Data on First-in-Class Oral HIF-2α Inhibitor in Patients with Advanced Kidney Cancer at 2016 ASCO Annual Meeting

  • Lead investigational compound PT2385 well tolerated with no dose-limiting toxicities
  • Initial signs of efficacy include 1 complete responder, 3 partial responders, and stable disease in 16 patients for 16 or more weeks
  • To date, 10 percent of patients remain in study for at least one year; study ongoing

Link to Article

ASCO Annual Meeting 2016
June 6, 2016 10:00AM Central Daylight Time